Ambiguous And Stifling: Pharma On ICH Bioanalytical Method Validation Guide
EU pharma is concerned that certain proposals in a new international guideline on bioanalytical method validation could be overinterpreted, increase burden on companies and stifle ‘scientific freedom.’
You may also be interested in...
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.